Showing 118 results
March 2017
-
Media Release
Novartis’ secukinumab is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with secukinumab may be achievable for around 20% of patients following one year of treatment1 Patients with longer disease duration before treatment… -
Media Release
Novartis partners with ADB, Swiss Embassy to hold forum on achieving universal health coverage in developing countries
Swiss and Filipino stakeholders in the healthcare sector gather at the Asian Development Bank (ADB) headquarters in Mandaluyong City to present and learn from innovative health policies and… -
Media Release
Novartis global survey shows 85% fear blindness, but only 33% have regular eye examination
Survey shows 85% of respondents are most afraid to lose eye sight of their five senses, 87% of respondents believe regular eye exams are important but only 33% reported visiting annual screenings… -
Media Release
Novartis partners with Philippine Glaucoma Society to help prevent blindness, promote regular eye exams
In line with World Glaucoma Week, Novartis signed a Memorandum of Agreement with the Philippine Glaucoma Society to promote awareness on glaucoma and the importance of regular eye examinations, as…